Richard H Weisler1, Ann C Childress. 1. Department of Psychiatry, University of North Carolina, Chapel Hill School of Medicine, Chapel Hill, and Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, North Carolina (Dr Weisler); and Department of Family Practice, Center for Psychiatry and Behavioral Medicine, Inc, Las Vegas, Nevada, and Department of Psychiatry at the University of Nevada School of Medicine, Reno (Dr Childress).
Abstract
OBJECTIVE: To review the efficacy, safety, and abuse liability of approved treatments in adults with attention-deficit/hyperactivity disorder (ADHD), with a focus on once-daily medications. DATA SOURCES: PubMed was searched for relevant studies/reviews in English from 2002 to 2011 on adult ADHD treatments. STUDY SELECTION: Keywords used in the search were ADHD, adults, and treatment. Limits included only clinical trials, meta-analyses, randomized controlled trials, and reviews including adults (aged ≥ 19 years). DATA EXTRACTION: Selection criteria returned 471 publications. Retrieved studies were excluded if they primarily focused on children, treatments not indicated for ADHD, or ADHD and comorbid conditions. DATA SYNTHESIS: An epidemiologic survey revealed that 10.9% of adults identified with ADHD had received treatment during the prior 12 months. Treatments for ADHD in adults include pharmacologic and nonpharmacologic options. US Food and Drug Administration-approved long-acting stimulants and a nonstimulant with proven efficacy and safety profiles have been developed and include osmotic-release oral system methylphenidate hydrochloride (OROS-methylphenidate), extended-release dexmethylphenidate hydrochloride, mixed amphetamine salts extended release (MAS-XR), the nonstimulant atomoxetine hydrochloride, and the prodrug lisdexamfetamine dimesylate. Long-acting stimulants differ in formulation characteristics used to achieve extended release, with OROS-methylphenidate employing an osmotic-release technology, extended-release dexmethylphenidate hydrochloride and MAS-XR using pH-dependent beads, and lisdexamfetamine dimesylate using prodrug technology. These features variably affect pharmacokinetic characteristics, duration of action, and abuse liability. While all long-acting medications have varied pharmacokinetic features, mechanism of action, and duration of effect, all are generally efficacious and safety profiles are similar. CONCLUSION: Approved long-acting treatments in adults with ADHD were effective in improving symptoms and were generally well tolerated.
OBJECTIVE: To review the efficacy, safety, and abuse liability of approved treatments in adults with attention-deficit/hyperactivity disorder (ADHD), with a focus on once-daily medications. DATA SOURCES: PubMed was searched for relevant studies/reviews in English from 2002 to 2011 on adult ADHD treatments. STUDY SELECTION: Keywords used in the search were ADHD, adults, and treatment. Limits included only clinical trials, meta-analyses, randomized controlled trials, and reviews including adults (aged ≥ 19 years). DATA EXTRACTION: Selection criteria returned 471 publications. Retrieved studies were excluded if they primarily focused on children, treatments not indicated for ADHD, or ADHD and comorbid conditions. DATA SYNTHESIS: An epidemiologic survey revealed that 10.9% of adults identified with ADHD had received treatment during the prior 12 months. Treatments for ADHD in adults include pharmacologic and nonpharmacologic options. US Food and Drug Administration-approved long-acting stimulants and a nonstimulant with proven efficacy and safety profiles have been developed and include osmotic-release oral system methylphenidate hydrochloride (OROS-methylphenidate), extended-release dexmethylphenidate hydrochloride, mixed amphetamine salts extended release (MAS-XR), the nonstimulant atomoxetine hydrochloride, and the prodrug lisdexamfetamine dimesylate. Long-acting stimulants differ in formulation characteristics used to achieve extended release, with OROS-methylphenidate employing an osmotic-release technology, extended-release dexmethylphenidate hydrochloride and MAS-XR using pH-dependent beads, and lisdexamfetamine dimesylate using prodrug technology. These features variably affect pharmacokinetic characteristics, duration of action, and abuse liability. While all long-acting medications have varied pharmacokinetic features, mechanism of action, and duration of effect, all are generally efficacious and safety profiles are similar. CONCLUSION: Approved long-acting treatments in adults with ADHD were effective in improving symptoms and were generally well tolerated.
Authors: Margaret Weiss; Steven A Safren; Mary V Solanto; Lily Hechtman; Anthony L Rostain; J Russell Ramsay; Candice Murray Journal: J Atten Disord Date: 2008-05 Impact factor: 3.256
Authors: Caroline S Stevenson; Stephanie Whitmont; Laurel Bornholt; David Livesey; Richard J Stevenson Journal: Aust N Z J Psychiatry Date: 2002-10 Impact factor: 5.744
Authors: David Michelson; Lenard Adler; Thomas Spencer; Frederick W Reimherr; Scott A West; Albert J Allen; Douglas Kelsey; Joachim Wernicke; Anthony Dietrich; Denái Milton Journal: Biol Psychiatry Date: 2003-01-15 Impact factor: 13.382
Authors: Mary B Haffey; Mary Buckwalter; Pinggao Zhang; Robert Homolka; Patrick Martin; Kenneth C Lasseter; James C Ermer Journal: Postgrad Med Date: 2009-09 Impact factor: 3.840
Authors: Frances R Levin; John J Mariani; Sheila Specker; Marc Mooney; Amy Mahony; Daniel J Brooks; David Babb; Yun Bai; Lynn E Eberly; Edward V Nunes; John Grabowski Journal: JAMA Psychiatry Date: 2015-06 Impact factor: 21.596
Authors: Tamás Treuer; Susan Shur-Fen Gau; Luis Méndez; William Montgomery; Julie A Monk; Murat Altin; Shenghu Wu; Chaucer C H Lin; Héctor J Dueñas Journal: J Child Adolesc Psychopharmacol Date: 2013-04-06 Impact factor: 2.576
Authors: Elisabeth Schapperer; Heike Daumann; Stéphane Lamouche; Ursula Thyroff-Friesinger; François Viel; Werner Weitschies Journal: Pharmacol Res Perspect Date: 2015-01-05
Authors: Martin A Katzman; Greg Mattingly; Larry J Klassen; Marc J Cataldo; Graeme A E Donnelly Journal: J Clin Psychopharmacol Date: 2020 Nov/Dec Impact factor: 3.118